Pharmacotherapy in sickle cell disease—state of the art and future prospects. (ανοίγει νέο παράθυρο)

Hankins J, Aygun B.

Πηγή‎: Br J Haematol 2009;145(3):296-308.

Καταχώριση‎: PubMed 19222472

DOI‎: 10.1111/j.1365-2141.2009.07602.x

https://www.ncbi.nlm.nih.gov/pubmed/19222472 (ανοίγει νέο παράθυρο)

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. (ανοίγει νέο παράθυρο)

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

Πηγή‎: Blood 2005;106(7):2269-75.

Καταχώριση‎: PubMed 16172253

DOI‎: 10.1182/Blood-2004-12-4973

https://www.ncbi.nlm.nih.gov/pubmed/16172253 (ανοίγει νέο παράθυρο)

Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa. (ανοίγει νέο παράθυρο)

John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE

Πηγή‎: N Engl J Med 2020;382(26):2524-33.

Καταχώριση‎: PubMed 32579813

DOI‎: 10.1056/NEJMoa2000146

https://www.ncbi.nlm.nih.gov/pubmed/32579813 (ανοίγει νέο παράθυρο)

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. (ανοίγει νέο παράθυρο)

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Πηγή‎: Br J Haematol 2013;161(6):852-60.

Καταχώριση‎: PubMed 23590693

DOI‎: 10.1111/bjh.12323

https://www.ncbi.nlm.nih.gov/pubmed/23590693 (ανοίγει νέο παράθυρο)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. (ανοίγει νέο παράθυρο)

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Πηγή‎: Arch Dis Child 2013;98(11):908-14.

Καταχώριση‎: PubMed 23995076

DOI‎: 10.1136/archdischild-2012-302387

https://www.ncbi.nlm.nih.gov/pubmed/23995076 (ανοίγει νέο παράθυρο)

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. (ανοίγει νέο παράθυρο)

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Πηγή‎: Pediatrics 2008;122(6):1332-42.

Καταχώριση‎: PubMed 19047254

DOI‎: 10.1542/peds.2008-0441

https://www.ncbi.nlm.nih.gov/pubmed/19047254 (ανοίγει νέο παράθυρο)

Impact of hydroxyurea on clinical events in the BABY HUG trial. (ανοίγει νέο παράθυρο)

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Πηγή‎: Blood 2012;120(22):4304-10.

Καταχώριση‎: PubMed 22915643

DOI‎: 10.1182/blood-2012-03-419879

https://www.ncbi.nlm.nih.gov/pubmed/22915643 (ανοίγει νέο παράθυρο)

Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. (ανοίγει νέο παράθυρο)

Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE; REACH Investigators

Πηγή‎: N Engl J Med 2019;380(2):121-31.

Καταχώριση‎: PubMed 30501550

DOI‎: 10.1056/NEJMoa1813598

https://www.ncbi.nlm.nih.gov/pubmed/30501550 (ανοίγει νέο παράθυρο)

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. (ανοίγει νέο παράθυρο)

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

Πηγή‎: J Pediatr 2002;140(2):225-9.

Καταχώριση‎: PubMed 11865275

DOI‎: 10.1067/mpd.2002.121383

https://www.ncbi.nlm.nih.gov/pubmed/11865275 (ανοίγει νέο παράθυρο)

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. (ανοίγει νέο παράθυρο)

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Πηγή‎: Pediatrics 2013;132(4):677-83.

Καταχώριση‎: PubMed 23999955

DOI‎: 10.1542/peds.2013-0333

https://www.ncbi.nlm.nih.gov/pubmed/23999955 (ανοίγει νέο παράθυρο)

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). (ανοίγει νέο παράθυρο)

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

Πηγή‎: Lancet 2011;377(9778):1663-72.

Καταχώριση‎: PubMed 21571150

DOI‎: 10.1016/S0140-6736(11)60355-3

https://www.ncbi.nlm.nih.gov/pubmed/21571150 (ανοίγει νέο παράθυρο)

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. (ανοίγει νέο παράθυρο)

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ.

Πηγή‎: Lancet 2016;387(10019):661-70.

Καταχώριση‎: PubMed 26670617

https://www.ncbi.nlm.nih.gov/pubmed/26670617 (ανοίγει νέο παράθυρο)

How I use hydroxyurea to treat young patients with sickle cell anemia. (ανοίγει νέο παράθυρο)

Ware RE.

Πηγή‎: Blood 2010;115(26):5300-11.

Καταχώριση‎: PubMed 20223921

DOI‎: 10.1182/blood-2009-04-146852

https://www.ncbi.nlm.nih.gov/pubmed/20223921 (ανοίγει νέο παράθυρο)

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. (ανοίγει νέο παράθυρο)

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Πηγή‎: Blood 2004;103(6):2039-45.

Καταχώριση‎: PubMed 14630791

DOI‎: 10.1182/blood-2003-07-2475

https://www.ncbi.nlm.nih.gov/pubmed/14630791 (ανοίγει νέο παράθυρο)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (ανοίγει νέο παράθυρο)

Hirst C, Owusu-Ofori S.

Πηγή‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Καταχώριση‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (ανοίγει νέο παράθυρο)

Sickle cell disease. (ανοίγει νέο παράθυρο)

Meremikwu MM, Okomo U.

Πηγή‎: BMJ Clin Evid 2011;02:2402.

Καταχώριση‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (ανοίγει νέο παράθυρο)

A phase 3 trial of l-glutamine in sickle cell disease. (ανοίγει νέο παράθυρο)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Πηγή‎: N Engl J Med 2018;379(3):226-35.

Καταχώριση‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (ανοίγει νέο παράθυρο)

Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. (ανοίγει νέο παράθυρο)

Olupot-Olupot P, Tomlinson G, Williams TN, Tshilolo L, Santos B, Smart LR, McElhinney K, Howard TA, Aygun B, Stuber SE, Lane A, Latham TS, Ware RE

Πηγή‎: Blood. 2023 23;141(12):1402-10.

Καταχώριση‎: PubMed 36375125

DOI‎: 10.1182/blood.2022017051

https://pubmed.ncbi.nlm.nih.gov/36375125/ (ανοίγει νέο παράθυρο)

Malaria chemoprophylaxis in sickle cell disease. (ανοίγει νέο παράθυρο)

Oniyangi O, Omari AA.

Πηγή‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Καταχώριση‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (ανοίγει νέο παράθυρο)